Peptide-Linked Drug Delivery for Non-Invasive Urinary Tract Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current intravesical chemotherapy treatments for urothelial carcinoma and other urinary tract diseases are invasive, lead to incomplete drug delivery, and fail to reach tumors outside the bladder, with high recurrence rates due to limited bladder retention time and systemic toxicity.
Innovation Solution
A systemically administered, negatively charged peptide (Bdd) that promotes renal clearance, minimizing off-target delivery and providing continuous drug excretion to the entire urothelial system, allowing for prolonged bladder retention and non-invasive treatment of urinary tract diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intravesical therapy is used to deliver drugs to the bladder, then drug delivery to the bladder is achieved, but the treatment is invasive and cannot reach tumors in the ureter or renal pelvis
Solution Approach 1:
The patent uses a peptide mediator that facilitates renal clearance of drugs from the bloodstream into the urinary tract. This intermediary mechanism enables systemic administration to achieve localized urinary tract delivery without direct invasive intervention, resolving the contradiction between comprehensive coverage and ease of operation
Solution Approach 2:
The invention creates a universal drug delivery system that can treat the entire urinary tract (bladder, ureter, renal pelvis) through a single systemic administration route. The peptide-based system performs multiple functions: systemic circulation, renal filtration, and urinary tract distribution, eliminating the need for separate invasive procedures for different urinary tract regions
2Quantity of substance
If intravesical therapy is used for bladder treatment, then direct bladder drug delivery is achieved, but bladder retention time is limited leading to incomplete drug delivery
Solution Approach 1:
The patent establishes continuous drug delivery to the bladder through renal clearance mechanisms. Instead of relying on limited passive retention after single administration, the system continuously filters and delivers drug-containing peptides from blood to urine, maintaining therapeutic drug presence in the bladder over extended periods and achieving complete drug delivery
3Quantity of substance
If systemically administered therapies are used to treat urinary system diseases, then comprehensive coverage of urinary tract is achieved, but systemic toxicity occurs
Solution Approach 1:
The patent applies local quality by modifying the peptide structure to contain specific amino acid sequences that are selectively reabsorbed or retained in the urinary tract after renal filtration. This creates localized high drug concentration in the urinary system while systemic levels remain low, achieving comprehensive urinary tract coverage without systemic toxicity
Solution Approach 2:
The peptide acts as a mediator that directs drug distribution specifically to the urinary system through renal clearance pathways. This intermediary function concentrates the therapeutic agent in the target organ (urinary tract) while minimizing exposure to other systemic tissues, resolving the contradiction between comprehensive coverage and systemic toxicity
4Quantity of substance
If invasive catheterization is used for intravesical therapy, then direct drug delivery to bladder is achieved, but patient compliance deteriorates due to pain and infection risk
Solution Approach 1:
The patent replaces the mechanical invasive catheterization system with a biochemical delivery system based on renal clearance. Instead of using physical tubes and direct bladder instillation, the system uses the body's natural kidney filtration mechanism to deliver drugs to the urinary tract, eliminating mechanical invasion while maintaining drug delivery efficiency and improving patient compliance
Data Source
AI summary
The present disclosure relates to a systemically administered peptide delivery platform that biodistributes to the kidney or urinary tract. The disclosure further relates to methods of treating a disease of the kidney or urinary tract in a subject in need thereof.